Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sodium Intake in Chronic Kidney Disease (STICK): A Randomised Controlled Trial
Brief Summary: Chronic kidney disease, which affects an estimated 300,000 people in Ireland and over 50 million people in the developed world, is responsible for a considerable burden of premature mortality and morbidity. All patients with chronic kidney disease are recommended low salt diets, i.e. less than a teaspoon of salt per day (which is \<5-6g of salt, which contains \<2-2.3g of sodium). The average intake in the general population is double the recommended intake, between 1-2 teaspoons per day, which is considered 'moderate' intake. In patients with hypertension, reducing from moderate (average) to low intake is associated with a small reduction in blood pressure. However, achieving this low target salt intake is difficult, and can have a negative knock-on effect on other healthy dietary factors and kidney hormones. In addition, there is no convincing research to show that patients with chronic kidney disease and normal blood pressure benefit from low salt intake. In fact, the small amount of research that does exist shows that the change in kidney function is the same in people who consume low salt diets (\<1 teaspoon) and moderate (1-2 teaspoons=average intake) salt diets. Moreover, there are some small studies that report that low-salt diets may increase the risk of death due to heart disease. Given that all patients with chronic kidney impairment are recommended a low-salt diet, it is important that we confirm that this recommendation truly benefits patients. In this randomized controlled trial, we hope to determine whether recommending a low salt intake, compared to average/moderate intake, is associated with a slower rate of decline in kidney function in patients with chronic kidney impairment. The results of this study will provide information to guide future research that will have critical implications for management of patients with chronic kidney disease.


Options:
A: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME
B: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control
C: Arm Label: Sodium Reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Sodium Reduction | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sodium Reduction; Assigned to Arm(s): Sodium Reduction
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: OxSalt care bundle | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: OxSalt care bundle; Assigned to Arm(s): Intervention

Answer: C